Evidence map›Paper›PMID 35258315›Full record

ReviewClinical microbiology reviews2022

Digital PCR Applications in the SARS-CoV-2/COVID-19 Era: a Roadmap for Future Outbreaks.

Raphael Nyaruaba, Caroline Mwaliko, David Dobnik, Pavel Neužil, Patrick Amoth, Matilu Mwau, Junping Yu, Hang Yang, Hongping Wei

Erratum issuedAbstract readReview
In one paragraph

Review in Clinical microbiology reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Raphael NyaruabaKey Laboratory of Special Pathogens and Biosafety, Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, China.ORCID 0000-0001-8467-8959
Caroline MwalikoInternational College, University of Chinese Academy of Sciences, Beijing, China.ORCID 0000-0002-3452-6321
David DobnikDepartment of Biotechnology and Systems Biology, National Institute of Biologygrid.419523.8, Ljubljana, Slovenia.
Pavel NeužilNorthwestern Polytechnical University, Xi'an, Shaanxi, China.
Patrick AmothMinistry of Health, Government of Kenya, Nairobi, Kenya.
Matilu MwauCenter for Infectious and Parasitic Diseases Control Research, Kenya Medical Research Institute, Busia, Kenya.
Junping YuKey Laboratory of Special Pathogens and Biosafety, Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, China.
Hang YangKey Laboratory of Special Pathogens and Biosafety, Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, China.ORCID 0000-0001-6750-1465
Hongping WeiKey Laboratory of Special Pathogens and Biosafety, Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, China.ORCID 0000-0002-9948-8880

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a global public health disaster. The current gold standard for the diagnosis of infected patients is real-time reverse transcription-quantitative PCR (RT-qPCR). As effective as this method may be, it is subject to false-negative and -positive results, affecting its precision, especially for the detection of low viral loads in samples. In contrast, digital PCR (dPCR), the third generation of PCR, has been shown to be more effective than the gold standard, RT-qPCR, in detecting low viral loads in samples. In this review article, we selected publications to show the broad-spectrum applications of dPCR, including the development of assays and reference standards, environmental monitoring, mutation detection, and clinical diagnosis of SARS-CoV-2, while comparing it analytically to the gold standard, RT-qPCR. In summary, it is evident that the specificity, sensitivity, reproducibility, and detection limits of RT-dPCR are generally unaffected by common factors that may affect RT-qPCR. As this is the first time that dPCR is being tested in an outbreak of such a magnitude, knowledge of its applications will help chart a course for future diagnosis and monitoring of infectious disease outbreaks.

Indexed as

COVID-19SARS-CoV-2COVID-19 TestingHumansPandemicsReal-Time Polymerase Chain ReactionReproducibility of ResultsSensitivity and SpecificityCOVID-19ddPCRdiagnosisquantificationRT-dPCRRT-qPCRSARS-CoV-2viral load

Identifiers

PMID35258315
PMCPMC9491181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.